RIGL: Rigel Pharmaceuticals Growth-Adjusted Market Cap to Net Income
Rigel Pharmaceuticals (RIGL) develops targeted therapies to combat oncology and blood disorders. The growth stock attractiveness indicator links these developments to revenues from thrombocytopenia treatment, which are provided by hematologists and insurance funds. The transition to mass drug sales is expanding business margins, while the indicator remains around 0.00, helping to determine the company's fair value.
Metric breakdowns and analytics for Rigel Pharmaceuticals (RIGL)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Rigel Pharmaceuticals|RIGL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio rigel.com|RIGL - Company Aggregate Debts|Debts to Book Value Rigel Pharmaceuticals Inc|RIGL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rigel Pharmaceuticals|Interim Coverage Ratio rigel.com
- business earnings and investment ratios data:
RIGL - Net Profit|Projected Net Profit Rigel Pharmaceuticals|RIGL - P/E Multiple|Projected Price to Earnings Ratio Rigel Corp|RIGL - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals Inc|RIGL - Operating profit before deduction of amortization|Earnings per share for the trailing year Rigel Pharmaceuticals|RIGL - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months rigel.com|RIGL - Earnings growth in current year|Expected earnings per share trend next year Rigel Pharmaceuticals
General company analysis:RIGL - Rigel Pharma
To identify undervalued assets, investors must compare the P/E market multiple with projected earnings growth. This metric measures the cost per unit of future growth, where a value below one signals a potential discount, which, combined with the impeccable reputation of Rigel Pharmaceuticals (RIGL) in oncology, allows for an assessment of business resilience to market volatility via the historical PEG ratio.
Competitors of Rigel Pharmaceuticals
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio PHVS (Pharvaris Pharma)|ABCL: PEG Multiple|TRML - Growth-Adjusted Market Cap to Net Income|PGEN (Precigen) - PEG Multiple|PHAR - Price to Net Income Growth Ratio|PEG Multiple NKTR|UPB - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Zenas Biopharma Inc ZBIO|immunome.com - Price/Earnings to Growth Ratio|GOSS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio KALV (KalVista Pharma)|Septerna Corp (SEPN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio PVLA (Pieris Corp)|SVRA (Savara Inc.) - PEG Multiple|ANAB: Growth-Adjusted Payback Ratio|PEG Multiple ATXS|PEG Multiple enGene Holdings Inc (ENGN)|Price/Earnings to Growth Ratio RAPT Therapeutics, Inc. RAPT|Growth-Adjusted Payback Ratio JBIO|ACRS - Price/Earnings to Growth Ratio|kyvernatx.com (KYTX) - Price/Earnings to Growth Multiple|TLSA: PEG Multiple|Cabaletta Bio Inc. (CABA) - PEG Multiple|VTYX (Ventyx Bio) - PEG Multiple|Price/Earnings to Growth Multiple Theratechnologies, Inc (THTX)|PEG Multiple AVTX|ELDN - Price to Earnings Adjusted for Growth Rate|Agenus Inc. - Price/Earnings to Growth Multiple|PEG Multiple Climb Bio Inc. CLYM|ZURA: Price/Earnings to Growth Multiple|aTyr Pharmaceuticals - Company Value to Earnings Growth Ratio|ADAG: PEG Multiple|IMA - Growth-Adjusted Market Cap to Net Income|STTK (Shattuck Labs Inc) - PEG Multiple|Price/Earnings to Growth Multiple Equillium Bio (EQ)|PEG Multiple CNTB|PEG Multiple immunic-therapeutics.com (IMUX)|Price/Earnings to Growth Ratio Atara Bio ATRA|InflaRx NV - Price/Earnings to Growth Ratio|XFOR - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Adicet Bio ACET|celularity.com (CELU) - Price/Earnings to Growth Ratio|INmune Bio Corporation - Growth-Adjusted Payback Ratio|BRNS (Barinthus Biotherapeutics) - PEG Multiple|kezarlifesciences.com (KZR) - Growth-Adjusted Market Cap to Net Income|PEG Multiple SABS|Akari Therapeutics PLC (AKTX) - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|Q32 Bio Inc - Price/Earnings to Growth Ratio|GOVX - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio EDSA|IBIO: PEG Multiple|Carisma Therapeutics Inc. - Growth-Adjusted Payback Ratio|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG Multiple|PEG Multiple Bolt Bio|Price/Earnings to Growth Ratio HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio AIM ImmunoTech AIM|ADTX - Price/Earnings to Growth Multiple|GRI Bio Corp - PEG Multiple|XRTX - PEG Multiple|HIND (Vyome Holdings Inc) - Price/Earnings to Growth Multiple|revbiosciences.com - Growth-Adjusted Payback Ratio|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|Scinai Immunotherapeutics Ltd (SCNI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|Price/Earnings to Growth Multiple affimed.com AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK - Price/Earnings to Growth Multiple|IGMS: Price/Earnings to Growth Multiple|ITOS - PEG Multiple|Ocean Bio (OCEA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TCBP|THRD (Third Harmonic Bio) - PEG Multiple
